Breastfeeding or standard infant formulas, alongside phenylalanine (Phe)-free protein substitutes, constitute the dietary management for infants with PKU to guarantee protein requirements are met in compliance with metabolic tolerance. This work aims to analyse the nutritional composition of Phe-free infant protein substitutes, in terms of macronutrients, micronutrients and functional components, available for PKU dietary management in Italy. A total of seven infant Phe-free protein substitutes were included in this review, six powder and one liquid. A second analysis was conducted to compare them to the composition of formulas intended for healthy infants, taking into consideration the Commission Delegated Regulation (EU) 2016/127 and Commission Delegated Regulation (EU) 2016/128 for micronutrients. The analysis revealed heterogeneity among protein substitutes suitable for infants with PKU. The energy and protein equivalents (P.Eq.) content are different; all of the substitutes contain docosahexaenoic acid (DHA) and arachidonic acid (ARA), while eicosapentaenoic acid (EPA), fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), human milk oligosaccharides (HMOs) and nucleotides are not present in all the substitutes. More attention should be paid to these infant products to ensure metabolic control of PKU, and also promote proper growth, cognitive neurodevelopment, favourable gut microbiota composition, and immune system health, while reducing the risk for non-communicable diseases (NCDs).

Are Phe-Free Protein Substitutes Available in Italy for Infants with PKU All the Same? / E. Verduci, M. Tosi, C. Montanari, M. Gambino, F. Eletti, A. Bosetti, M. Di Costanzo, M.T. Carbone, G. Biasucci, L. Fiori, G. Zuccotti. - In: NUTRIENTS. - ISSN 2072-6643. - 16:1(2023 Dec), pp. 30.1-30.21. [10.3390/nu16010030]

Are Phe-Free Protein Substitutes Available in Italy for Infants with PKU All the Same?

E. Verduci
Primo
;
M. Tosi
Secondo
;
C. Montanari;M. Gambino;F. Eletti;L. Fiori;G. Zuccotti
Ultimo
2023

Abstract

Breastfeeding or standard infant formulas, alongside phenylalanine (Phe)-free protein substitutes, constitute the dietary management for infants with PKU to guarantee protein requirements are met in compliance with metabolic tolerance. This work aims to analyse the nutritional composition of Phe-free infant protein substitutes, in terms of macronutrients, micronutrients and functional components, available for PKU dietary management in Italy. A total of seven infant Phe-free protein substitutes were included in this review, six powder and one liquid. A second analysis was conducted to compare them to the composition of formulas intended for healthy infants, taking into consideration the Commission Delegated Regulation (EU) 2016/127 and Commission Delegated Regulation (EU) 2016/128 for micronutrients. The analysis revealed heterogeneity among protein substitutes suitable for infants with PKU. The energy and protein equivalents (P.Eq.) content are different; all of the substitutes contain docosahexaenoic acid (DHA) and arachidonic acid (ARA), while eicosapentaenoic acid (EPA), fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), human milk oligosaccharides (HMOs) and nucleotides are not present in all the substitutes. More attention should be paid to these infant products to ensure metabolic control of PKU, and also promote proper growth, cognitive neurodevelopment, favourable gut microbiota composition, and immune system health, while reducing the risk for non-communicable diseases (NCDs).
phenylketonuria; infant nutrition; Phe-free protein substitutes; docosahexaenoic acid; arachidonic acid; biotics; non-communicable diseases prevention;
Settore MED/38 - Pediatria Generale e Specialistica
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
   AN APP TO SHED THE LIGHT ON THE WINDOW OF OPPORTUNITY OF THE FIRST 1000 DAYS OF LIFE
   MINISTERO DELL'UNIVERSITA' E DELLA RICERCA
   202247M2AP_004
dic-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
nutrients-16-00030.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 288.09 kB
Formato Adobe PDF
288.09 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1021538
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact